- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06846671
Une étude du BGB-16673 par rapport au choix de l'investigateur chez les participants atteints de leucémie lymphocytaire chronique auparavant exposée à la fois à la Bruton Tyrosine kinase (BTK) et aux inhibiteurs de la leucémie / lymphome 2 à cellules B (BCL2) (CaDAnCe-302)
Une phase 3, une étude randomisée en phase 3 du BGB-16673 par rapport au choix de l'investigateur (Idelalisib plus rituximab ou bendamustine plus rituximab ou vénémié plus vénémière plus au rituximab) chez les patients atteints d'inhibiteurs chroniques lymphocytiques
The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Chronic lymphocytic leukemia is a type of blood cancer that affects people around the world. People with CLL suffer from enlarged lymph nodes, spleen, or liver, or have symptoms like night sweats, weight loss and fever. They have shorter life expectancy compared to healthy people. There is an urgent need for new treatment to prolong life and control disease-related symptoms.
In this study, participants with relapsed/refractory (R/R) CLL who were previously exposed to a BTKi and a BCL2i will receive tacabrutideg or the investigator's choice of idelalisib plus rituximab (for CLL only) or bendamustine plus rituximab or venetoclax plus rituximab retreatment. The main purpose of this study is to compare the length of time that participants live without their CLL or SLL worsening between those participants who receive tacabrutideg versus the investigator's choice of treatment (idelalisib plus rituximab or bendamustine plus rituximab, or venetoclax plus rituximab).
Approximately 250 participants will be included in this study around the world. Participants will be randomly allocated to receive either tacabrutideg or the investigator's choice of treatment.
"Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website."
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Study Director
- Numéro de téléphone: 1.877.828.5568
- E-mail: clinicaltrials@beonemed.com
Lieux d'étude
-
-
-
Augsburg, Allemagne, 86156
- Recrutement
- Universitatsklinikum Augsburg
-
Berlin, Allemagne, 10715
- Recrutement
- Praxis Am Volkspark
-
Chemnitz, Allemagne, 09116
- Recrutement
- Klinikum Chemnitz Ggmbh
-
Essen, Allemagne, 45122
- Recrutement
- Universitatsklinikum Essen (Aor)
-
Frankfurt am Main, Allemagne, 60389
- Recrutement
- Centrum Fur Haematologie Und Onkologie Bethanien
-
Freiburg im Breisgau, Allemagne, 79106
- Recrutement
- Universitatsklinikum Freiburg I Br Klinik Fur Innere Medizin I
-
Hamburg, Allemagne, 20251
- Recrutement
- Universitatsklinikum Hamburg Eppendorf
-
Heidelberg, Allemagne, 69120
- Recrutement
- Universitatsklinikum Heidelberg
-
Homburg, Allemagne, 66421
- Recrutement
- Universitatsklinikum Des Saarlandes
-
Koblenz, Allemagne, 56068
- Recrutement
- Invo Institut Fur Versorgungsforschung in Der Onkologie
-
Leipzig, Allemagne, 04103
- Recrutement
- Universitaetsklinikum Leipzig Aor
-
Münster, Allemagne, 48149
- Recrutement
- Universitatsklinikum Munster Medizinische Klinik A
-
-
-
-
-
Caba, Argentine, CP1114
- Recrutement
- FUNDALEU
-
Caba, Argentine, C1431
- Recrutement
- CEMIC
-
Caba, Argentine, 1425
- Recrutement
- Hospital Aleman
-
Ciudad Autonoma Buenos Aires, Argentine, 1413
- Recrutement
- Hospital Italiano de Buenos Aires
-
Ciudad Autonoma Buenos Aires, Argentine, 1426
- Recrutement
- Instituto Alexander Fleming (Iaf)
-
San Miguel de Tucumán, Argentine, 4000
- Recrutement
- Cice 9 de Julio Sanatorio 9 de Julio
-
-
-
-
New South Wales
-
Concord, New South Wales, Australie, NSW 2139
- Recrutement
- Concord Repatriation General Hospital
-
Gosford, New South Wales, Australie, NSW 2250
- Recrutement
- Gosford Hospital
-
Port Macquarie, New South Wales, Australie, NSW 2444
- Recrutement
- Port Macquarie Base Hospital
-
Randwick, New South Wales, Australie, NSW 2031
- Recrutement
- Prince of Wales Hospital
-
-
Queensland
-
Toowoomba, Queensland, Australie, QLD 4350
- Recrutement
- Toowoomba Hospital
-
-
South Australia
-
Bedford PK, South Australia, Australie, SA 5042
- Recrutement
- Flinders Medical Centre
-
-
Victoria
-
Melbourne, Victoria, Australie, VIC 3004
- Recrutement
- The Alfred Hospital
-
-
Western Australia
-
West Perth, Western Australia, Australie, WA 6005
- Recrutement
- Perth Blood Institute
-
-
-
-
-
Belo Horizonte, Brésil, 30110-022
- Recrutement
- CETUS
-
Brasília, Brésil, 70200-730
- Recrutement
- Hospital Sirio Libanes Brasilia
-
Curitiba, Brésil, 81520-060
- Recrutement
- Hospital Erasto Gaertner
-
Florianópolis, Brésil, 88020-210
- Recrutement
- Centro de Ensino E Pesquisa Em Oncologia de Santa Catarina (Cepen)
-
Joinville, Brésil, 89201-260
- Recrutement
- Instituto Joinvilense de Hematologia E Oncologia
-
Niterói, Brésil, 24020-096
- Recrutement
- Complexo Hospitalar de Niteroi
-
Porto Alegre, Brésil, 90110-270
- Recrutement
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
-
Rio de Janeiro, Brésil, 22250-040
- Recrutement
- Oncoclinicas Rio de Janeiro Sa
-
Rio de Janeiro, Brésil, 22061-080
- Recrutement
- Hospital Sao Lucas Dasa Oncologia
-
Salvador, Brésil, 41253-190
- Recrutement
- Hospital Sao Rafael (Rede Dor)
-
São Paulo, Brésil, 05652-900
- Recrutement
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brésil, 04014-002
- Recrutement
- Instituto Brasileiro de Controle Do Cancer
-
São Paulo, Brésil, 01401-004
- Recrutement
- Instituto Dor de Pesquisa E Ensino Sao Paulo
-
Vitória, Brésil, 29043-260
- Recrutement
- Hospital Santa Rita de Cassia Afecc
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Recrutement
- Juravinski Cancer Centre
-
London, Ontario, Canada, N6A 5W9
- Recrutement
- London Health Sciences Centre
-
Ottawa, Ontario, Canada, K1H 8L6
- Recrutement
- The Ottawa Hospital Cancer Centre
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Recrutement
- Centre Integre de Sante Et de Services Sociaux de La Monteregie Centre
-
Montreal, Quebec, Canada, QC H3t 1E2
- Recrutement
- Jewish General Hospital
-
SaintJerome, Quebec, Canada, J7Z 5T3
- Recrutement
- Unite de Recherche Clinique Du Cisss Des Laurentides
-
-
-
-
Busan Gwang'yeogsi
-
Seogu, Busan Gwang'yeogsi, Corée du Sud, 49201
- Recrutement
- Dong A University Hospital
-
-
Daegu Gwang'yeogsi
-
Junggu, Daegu Gwang'yeogsi, Corée du Sud, 41944
- Recrutement
- Kyungpook National University Hospital
-
-
Gyeonggi-do
-
IlsandongGu GoyangSi, Gyeonggi-do, Corée du Sud, 10408
- Recrutement
- National Cancer Center (Korea)
-
-
Jeonnam-Gwangju S.M. City
-
HwasunGun, Jeonnam-Gwangju S.M. City, Corée du Sud, 58128
- Recrutement
- Chonnam National University Hwasun Hospital
-
-
Seoul Teugbyeolsi
-
GangnamGu, Seoul Teugbyeolsi, Corée du Sud, 06351
- Recrutement
- Samsung Medical Center
-
SeochoGu, Seoul Teugbyeolsi, Corée du Sud, 06591
- Recrutement
- The Catholic University of Korea, Seoul St Marys Hospital
-
Seoul, Seoul Teugbyeolsi, Corée du Sud, 03080
- Recrutement
- Seoul National University Hospital
-
-
-
-
-
Bari, Italie, 70124
- Recrutement
- Irccs Istituto Tumori Giovanni Paolo Ii
-
Florence, Italie, 50134
- Recrutement
- Aou Careggi, Servizio Sanitario Toscana
-
Milan, Italie, 20132
- Recrutement
- Ospedale San Raffaele
-
Milan, Italie, 20122
- Recrutement
- Fondazione Irccs Ca Granda Ospedale Maggiore Policlinico
-
Naples, Italie, 80131
- Recrutement
- Azienda Ospedaliera Universitaria Federico Ii
-
Novara, Italie, 28100
- Recrutement
- Aou Maggiore Della Carita
-
Pavia, Italie, 27100
- Recrutement
- Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi
-
Perugia, Italie, 6129
- Recrutement
- Ospedale Santa Maria Della Misericordia
-
Roma, Italie, 00168
- Recrutement
- Fondazione Policlinico Universitario Agostino Gemelli
-
-
-
-
-
Kumamoto, Japon, 860-8556
- Recrutement
- Kumamoto University Hospital
-
Okayama, Japon, 701-1192
- Recrutement
- National Hospital Organization Okayama Medical Center
-
Osaka, Japon, 545-8586
- Recrutement
- Osaka Metropolitan University Hospital
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japon, 464-8681
- Recrutement
- Aichi Cancer Center Hospital Clinical Oncology
-
-
Chiba
-
Chiba, Chiba, Japon, 260-8717
- Recrutement
- Chiba Cancer Center
-
-
Ehime
-
Matsuyama, Ehime, Japon, 791-0280
- Recrutement
- Nho Shikoku Cancer Center
-
-
Hiroshima
-
Hiroshima, Hiroshima, Japon, 730-8619
- Recrutement
- Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
-
-
Hokkaido
-
Sapporo, Hokkaido, Japon, 064-0804
- Recrutement
- Aiiku Hospital
-
-
Hyōgo
-
AmagasakiCity, Hyōgo, Japon, 660-8550
- Recrutement
- Hyogo Prefectural Amagasaki General Medical Center
-
-
Kagoshima-ken
-
Kagoshima, Kagoshima-ken, Japon, 890-8520
- Recrutement
- Kagoshima University Hospital
-
-
Kyoto
-
KyotoShi, Kyoto, Japon, 602-8566
- Recrutement
- University Hospital, Kyoto Prefectural Univ of Medicine
-
-
Miyagi
-
Sendai, Miyagi, Japon, 980-8574
- Recrutement
- Tohoku University Hospital
-
-
Niigata
-
Niigata, Niigata, Japon, 951-8520
- Recrutement
- Niigata University Medical and Dental Hospital
-
-
Okayama-ken
-
Kurashikishi, Okayama-ken, Japon, 710-8602
- Recrutement
- Kurashiki Central Hospital
-
-
Osaka
-
Hirakata, Osaka, Japon, 573-1191
- Recrutement
- Kansai Medical University Hospital
-
Sakai, Osaka, Japon, 590-0197
- Recrutement
- Kindai University Hospital
-
-
Saitama
-
Kawagoeshi, Saitama, Japon, 350-8550
- Recrutement
- Saitama Medical Center
-
-
Tokyo
-
Bunkyoku, Tokyo, Japon, 113-8677
- Recrutement
- Tokyo Metropolitan Komagome Hospital
-
Shinagawaku, Tokyo, Japon, 141-0022
- Recrutement
- Ntt Medical Center Tokyo
-
-
-
-
-
Amsterdam, Pays-Bas, 1081 HV
- Recrutement
- Amsterdam Umc Vu Mc
-
-
-
-
-
Brzozów, Pologne, 36-200
- Recrutement
- Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
-
Katowice, Pologne, 40-519
- Recrutement
- Pratia Onkologia Katowice
-
Krakow, Pologne, 30-727
- Recrutement
- Pratia McM Krakow
-
Lodz, Pologne, 93-513
- Recrutement
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
-
Lublin, Pologne, 20-090
- Recrutement
- Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
-
Wroclaw, Pologne, 50-367
- Recrutement
- Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
-
-
-
-
-
Aberdeen, Royaume-Uni, AB25 2ZN
- Recrutement
- Aberdeen Royal Infirmary
-
Birmingham, Royaume-Uni, B9 5SS
- Recrutement
- Birmingham Heartlands Hospital
-
Bournemouth, Royaume-Uni, BH7 7DW
- Recrutement
- The Royal Bournemouth and Christchurch Hospitals Nhs Foundation
-
London, Royaume-Uni, SW3 6JJ
- Recrutement
- Royal Marsden Hospital
-
London, Royaume-Uni, NW1 2PG
- Recrutement
- University College Hospital
-
Southampton, Royaume-Uni, SO16 6YD
- Recrutement
- Southampton General Hospital
-
-
-
-
-
Brno, Tchéquie, 625 00
- Recrutement
- Fakultni Nemocnice Brno
-
Hradec Králové, Tchéquie, 500 03
- Recrutement
- Fakultni Nemocnice Hradec Kralove
-
Ostrava, Tchéquie, 708 00
- Recrutement
- Fakultni Nemocnice Ostrava
-
Prague, Tchéquie, 10000
- Recrutement
- Vseobecna Fakultni Nemocnice V Praze
-
-
-
-
-
Ankara, Turquie (Türkiye), 6500
- Recrutement
- Gazi University
-
Ankara, Turquie (Türkiye), 06200
- Recrutement
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
-
Balçova, Turquie (Türkiye), 35330
- Recrutement
- Dokuz Eylul University
-
Dokuma, Turquie (Türkiye), 07025
- Recrutement
- Antalya Memorial Hospital
-
Sakarya, Turquie (Türkiye), 54100
- Recrutement
- Sakarya Training and Research Hospital
-
-
-
-
Arkansas
-
Jonesboro, Arkansas, États-Unis, 72401
- Recrutement
- St Bernards Medical Center
-
-
California
-
Los Angeles, California, États-Unis, 90095-3075
- Recrutement
- UCLA Department of Medicine Hematologyoncology
-
San Diego, California, États-Unis, 92103-2106
- Recrutement
- Scripps Prebys Cancer Center
-
Whittier, California, États-Unis, 90602
- Recrutement
- Pih Health Whittier Hospital
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80012-5405
- Recrutement
- Rocky Mountain Cancer Centers (Williams) Usor
-
Golden, Colorado, États-Unis, 80401
- Recrutement
- Intermountain Health Lutheran Hospital Cancer Center of Colorado
-
-
Florida
-
Fort Myers, Florida, États-Unis, 33912
- Recrutement
- Florida Oncology and Hematology
-
Jacksonville, Florida, États-Unis, 32207-8432
- Recrutement
- Baptist Md Anderson Cancer Center
-
Weston, Florida, États-Unis, 33331-3609
- Recrutement
- Cleveland Clinic Florida
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322-1013
- Recrutement
- Emory University Winship Cancer Institute
-
Atlanta, Georgia, États-Unis, 30342
- Recrutement
- Northside Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, États-Unis, 70808-4365
- Recrutement
- Our Lady of the Lake Hospital
-
-
Maryland
-
Bethesda, Maryland, États-Unis, 20817-7847
- Recrutement
- American Oncology Partners of Maryland Pa
-
-
Michigan
-
Grand Rapids, Michigan, États-Unis, 49503-2560
- Recrutement
- Corewell Health the Michigan Cancer Consortium
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55455-0341
- Recrutement
- University of Minnesota
-
-
Missouri
-
Chesterfield, Missouri, États-Unis, 63017
- Recrutement
- St Lukes Center For Cancer Care
-
Springfield, Missouri, États-Unis, 65807-5288
- Recrutement
- Oncology Hematology Associates
-
-
Montana
-
Billings, Montana, États-Unis, 59102-6746
- Recrutement
- St Vincent Frontier Cancer Center
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68130-2042
- Recrutement
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists
-
-
New York
-
New York, New York, États-Unis, 10065-6800
- Recrutement
- Memorial Sloan Kettering Cancer Center Mskcc
-
Shirley, New York, États-Unis, 11967
- Recrutement
- New York Cancer and Blood Specialists
-
Westbury, New York, États-Unis, 11590-5119
- Recrutement
- Optum Medical Care, Pc
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44106-1716
- Recrutement
- University Hospitals
-
Dayton, Ohio, États-Unis, 45415
- Recrutement
- Dayton Physician Network
-
-
Oregon
-
Eugene, Oregon, États-Unis, 97401
- Recrutement
- Oncology Associates of Oregon Willamette Valley Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15224
- Recrutement
- West Penn Hospital
-
York, Pennsylvania, États-Unis, 17403-5049
- Recrutement
- Cancer Care Associates of York
-
-
Texas
-
Temple, Texas, États-Unis, 76508-0001
- Recrutement
- Baylor Scott and White Health
-
Tyler, Texas, États-Unis, 75702-7522
- Recrutement
- Texas Oncology Tyler
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria.
- Previously received treatment for CLL/SLL with both a BTKi and a BCL2i.
- Participants with SLL must have measurable disease by computer tomography (CT)/magnetic resonance imaging (MRI)
- Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
- Adequate liver function
- Adequate blood clotting function
Exclusion Criteria:
- Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
- Prior autologous stem cell transplant or chimeric antigen receptor-T cell therapy in the last 3 months
- Known central nervous system involvement
- Prior exposure to any BTK protein degraders
- Active fungal, bacterial and/or viral infection requiring parenteral systemic therapy
- Clinically significant cardiovascular disease
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Arm A: Tacabrutideg monotherapy
Participants will receive tacabrutideg once daily until any of the treatment discontinuation criteria are met |
Administered orally
Autres noms:
|
|
Comparateur actif: Arm B: Investigator's Choice
Participants will receive investigator's choice of idelalisib plus rituximab for CLL only or bendamustine plus rituximab, or venetoclax plus rituximab retreatment. |
Administered orally Administered intravenously Administered intravenously Administered orally |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression-Free Survival (PFS) by Independent Review Committee (IRC)
Délai: Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL). |
Approximately 36 Months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall Survival (OS)
Délai: Approximately 36 Months
|
OS is defined as time from the date of randomization to the date of death due to any cause. |
Approximately 36 Months
|
|
Progression-Free Survival (PFS) in Participants with Prior Exposure to Noncovalent Bruton Tyrosine Kinase Inhibitor(s) (ncBTKi) by IRC
Délai: Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 iwCLL for participants with prior exposure to ncBTKi. |
Approximately 36 Months
|
|
PFS by the Investigator Assessment
Délai: Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by the investigator using modified 2018 iwCLL criteria for participants with CLL and Lugano classification for participants with SLL |
Approximately 36 Months
|
|
Overall Response Rate (ORR) by IRC and Investigator Assessment
Délai: Approximately 36 Months
|
ORR is defined as the percentage of participants with best overall response of complete response (CR), complete response with incomplete bone marrow recovery (Cri), nodular partial remission (nPR), or partial response (PR) as assessed by the IRC or by the investigator. |
Approximately 36 Months
|
|
Rate of Partial Response with Lymphocytosis (PR-L) or Higher Determined by IRC and by Investigator Assessment
Délai: Approximately 36 Months
|
Rate of PR-L or higher is defined as the percentage of participants with a best overall response of CR, CRi, nPR, PR, or PR-L as assessed by the IRC or by the Investigator |
Approximately 36 Months
|
|
Duration of Response (DOR) by IRC and Investigator Assessment
Délai: Approximately 36 Months
|
DOR is defined as the time from initial response to disease progression or death, whichever occurs first, as assessed by the IRC or by the investigator. |
Approximately 36 Months
|
|
Time to Next Anti-CLL/SLL Treatment (TTNT)
Délai: Approximately 36 Months
|
TTNT is defined as the time from the date of randomization to the date of next anti-CLL/SLL treatment. |
Approximately 36 Months
|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Délai: Approximately 36 Months
|
Safety will be assessed by monitoring and recording of all treatment emergent adverse events (AEs) graded by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. |
Approximately 36 Months
|
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Questionnaire -Core 30 (EORTC QLQ-C30) Global Health Status/QoL (GHS) and Physical Functioning Scales
Délai: Approximately 24 Months
|
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales(fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best). Higher scores in GHS and functional scales indicate better quality of life. |
Approximately 24 Months
|
|
Change from baseline in EORTC Quality of Life Questionnaire - Chronic Lymphocytic Leukemia Module 17 Items (QLQ-CLL17) Symptom Burden and Physical Condition Scales
Délai: Approximately 24 Months
|
The symptom burden and physical condition will be measured by QLQ-CLL17. EORTC QLQ-CLL17 comprises 17 items grouped into 3 multi-item scales: 1) symptom burden, 2) physical condition/fatigue, and 3) worries/fears about health and functioning. Each question is rated using a 4-point response scale ("not at all," "a little," "quite a bit," and "very much") and the recall period for all items is the past 7 days. The scores of each subscale are calculated based on the EORTC's protocol and then transformed to a 0 to 100 scale. Higher scores represent higher levels of symptom burden, physical condition/fatigue, or worries/fears about health and functioning. |
Approximately 24 Months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Study Director, BeOne Medicines
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs
- Maladie chronique
- Attributs de la maladie
- Maladies du système immunitaire
- Tumeurs par type histologique
- Maladies hématologiques
- Maladies lymphatiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Leucémie, cellule B
- Leucémie, Lymphoïde
- Leucémie
- Conditions pathologiques, signes et symptômes
- Maladies hémiques et lymphatiques
- Leucémie lymphocytaire chronique à cellules B
- Acides aminés, peptides et protéines
- Protéines
- Produits chimiques organiques
- Composés hétérocycliques
- Benzimidazoles
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Hydrocarbures
- Acides, acyclique
- Acides carboxyliques
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Composés de moutarde d'azote
- Composés moutarde
- Hydrocarbures, halogénés
- Butyrate
- Anticorps, monoclonal et murin
- Chlorhydrate de bendamustine
- Rituximab
- vénitoclax
- idelalisib
Autres numéros d'identification d'étude
- BGB-16673-302
- 2024-518893-15-00 (Ctis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Délai de partage IPD
See plan description
Critères d'accès au partage IPD
See plan description
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .